Donald E. Kohan

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

H. Heerspink, G. Kirsztajn, P. Canetta, 2023, The New England journal of medicine.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.